Clinical Trial Update: Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study evaluating Zirconium-89-labeled girentuximab for PET/CT imaging in renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Zirconium-89-girentuximab (girentuximab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Renal Cell Carcinoma | Phase 2, Phase 3 | Status: COMPLETED